Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Proposed criteria for the diagnosis of MOGAD

Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, describes the first attempt to propose diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). An international panel developed the newly proposed criteria, highlighting how MOG-IgG cell-based assays are important for diagnostic accuracy and should meet specific quality benchmarks. These proposed diagnostic criteria are now being validated across various patient cohorts. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Grants or contracts: German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall.
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene.
Participation on a Data Safety Monitoring Board or Advisory Board: Celgene, Roche, UCB, Merck.
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Academic Editor PLos One, Associate Editor von Neurology® Neuroimmunology & Neuroinflammation.